A detailed history of Exodus Point Capital Management, LP transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 278,302 shares of TGTX stock, worth $8.98 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
278,302
Previous 1,101,298 74.73%
Holding current value
$8.98 Million
Previous $19.6 Million 66.78%
% of portfolio
0.04%
Previous 0.13%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$17.21 - $25.28 $14.2 Million - $20.8 Million
-822,996 Reduced 74.73%
278,302 $6.51 Million
Q2 2024

Aug 13, 2024

BUY
$13.32 - $19.19 $7.19 Million - $10.4 Million
539,706 Added 96.1%
1,101,298 $19.6 Million
Q1 2024

May 14, 2024

BUY
$13.02 - $21.3 $4.77 Million - $7.8 Million
366,425 Added 187.75%
561,592 $8.54 Million
Q3 2023

Nov 09, 2023

BUY
$8.36 - $26.5 $330,378 - $1.05 Million
39,519 Added 25.39%
195,167 $1.63 Million
Q2 2023

Aug 10, 2023

BUY
$15.48 - $35.0 $2.04 Million - $4.62 Million
132,083 Added 560.5%
155,648 $3.87 Million
Q1 2023

May 11, 2023

BUY
$10.23 - $19.34 $241,069 - $455,747
23,565 New
23,565 $354,000
Q3 2022

Nov 10, 2022

BUY
$4.57 - $8.4 $380,077 - $698,611
83,168 Added 157.36%
136,021 $805,000
Q2 2022

Aug 19, 2022

BUY
$3.74 - $10.66 $15,794 - $45,017
4,223 Added 8.68%
52,853 $225,000
Q1 2022

May 13, 2022

BUY
$7.81 - $20.45 $379,800 - $994,483
48,630 New
48,630 $462,000
Q4 2019

Feb 14, 2020

SELL
$5.1 - $11.2 $116,672 - $256,222
-22,877 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$5.38 - $8.99 $435 - $728
81 Added 0.36%
22,877 $128,000
Q2 2019

Aug 14, 2019

BUY
$6.27 - $8.65 $142,930 - $197,185
22,796 New
22,796 $197,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.69B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.